The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Adverse Prognostic Significance of KIT Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study
Abstract
Purpose: To analyze the prognostic impact of mutated KIT (mutKIT) in core-binding factor acute myeloid leukemia (AML) with inv(16)(p13q22) and t(8;21)(q22;q22). Patients and Methods: Sixty-one adults with inv(16) and 49 adults with t(8;21), assigned to postremission therapy with repetitive cycles of higher dose cytarabine were analyzed for mutKIT in exon 17 (mutKIT17) and 8 (mutKIT8) by denaturing high-performance liquid chromatography and direct sequencing at diagnosis. The median follow-up was 5.3 years. Results: Among patients with inv(16), 29.5% had mutKIT (16% with mutKIT17 and 13% with sole mutKIT8). Among patients with t(8;21), 22% had mutKIT (18% with mutKIT17 and 4% with sole mutKIT8). Complete remission rates of patients with mutKIT and wild-type KIT (wtKIT) were similar in both cytogenetic groups. In inv(16), the cumulative incidence of relapse (CIR) was higher for patients with mutKIT (P = .05; 5-year CIR, 56% v 29%) and those with mutKIT17 (P = .002; 5-year CIR, 80% v 29%) compared with wtKIT patients. Once data were adjusted for sex, mutKIT predicted worse overall survival (OS). In t(8;21), mutKIT predicted higher CIR (P = .017; 5-year CIR, 70% v 36%), but did not influence OS. Conclusion: We report for the first time that mutKIT, and particularly mutKIT17, confer higher relapse risk, and both mutKIT17 and mutKIT8 appear to adversely affect OS in AML with inv(16). We also confirm the adverse impact of mutKIT on relapse risk in t(8;21) AML. We suggest that patients with core-binding factor AML should be screened for mutKIT at diagnosis for both prognostic and therapeutic purposes, given that activated KIT potentially can be targeted with novel tyrosine kinase inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International System for Human Cytogenetic Nomenclature
National Cancer Institute (2020) · Definitions · doi:10.32388/78qroa · Cited by 6,840
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors
Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., et al. (1998) · Science · doi:10.1126/science.279.5350.577 · Cited by 4,490
Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,655
GROWTH FACTOR RECEPTOR TYROSINE KINASES
Yarden, Y., & Ullrich, A. (1988) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.57.070188.002303 · Cited by 1,838
Slovak, M. L., Kopecky, K. J., Cassileth, P. A., Harrington, D. H., Theil, K. S., Mohamed, A., Paietta, E., Willman, C. L., Head, D. R., Rowe, J. M., et al. (2000) · Blood · doi:10.1182/blood.v96.13.4075 · Cited by 1,601
Byrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,597
Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand.
Yarden, Y., Kuang, W. J., Yang-Feng, T., Coussens, L., Munemitsu, S., Dull, T. J., Chen, E., Schlessinger, J., Francke, U., & Ullrich, A. (1987) · The EMBO Journal · doi:10.1002/j.1460-2075.1987.tb02655.x · Cited by 1,574
Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia
Mayer, R. J., Davis, R. B., Schiffer, C. A., Berg, D. T., Powell, B. L., Schulman, P., Omura, G. A., Moore, J. O., McIntyre, O. R., & Frei, E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311402 · Cited by 1,427
KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.
Rubin, B. P., Singer, S., Tsao, C., Duensing, A. U., Lux, M. L., Ruiz, R., Hibbard, M. K., Chen, C. J., Xiao, S., Tuveson, D. A., et al. (2001) · PubMed · Cited by 959
Nagata, H., Worobec, A. S., Oh, C. K., Chowdhury, B. A., Tannenbaum, S., Suzuki, Y., & Metcalfe, D. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.23.10560 · Cited by 872
Cheson, B. D., Cassileth, P. A., Head, D. R., Schiffer, C. A., Bennett, J. M., Bloomfield, C. D., Brunning, R., Gale, R. P., Grever, M. R., & Keating, M. J. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.5.813 · Cited by 770
Self-citationFusion Between Transcription Factor CBFβ/PEBP2β and a Myosin Heavy Chain in Acute Myeloid Leukemia
Liu, P., Tarlé, S. A., Hajra, A., Claxton, D. F., Marlton, P., Freedman, M., Siciliano, M. J., & Collins, F. S. (1993) · Science · doi:10.1126/science.8351518 · Cited by 732
Bloomfield, C. D., Lawrence, D. D., Byrd, J. C., Carroll, A. J., Pettenati, M. J., Tantravahi, R. V., Patil, S., Davey, F. R., Berg, D. T., Schiffer, C. A., et al. (1998) · PubMed · Cited by 682
Self-citationCytogenetics in acute leukemia
Mrózek, K., Heerema, N. A., & Bloomfield, C. D. (2004) · Blood Reviews · doi:10.1016/s0268-960x(03)00040-7 · Cited by 659
Self-citationLongley, B. J., Metcalfe, D. D., Tharp, M., Wang, X., Tyrrell, L., Lu, S.-Z., Heitjan, D., & Ma, Y. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1609 · Cited by 552
Schittenhelm, M. M., Shiraga, S., Schroeder, A., Corbin, A. S., Griffith, D., Lee, F. Y., Bokemeyer, C., Deininger, M. W. N., Druker, B. J., & Heinrich, M. C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2050 · Cited by 468
Effect of c-kit Mutation on Prognosis of Gastrointestinal Stromal Tumors
谷口, 正. (2001) · Cited by 438
Activating c-kit Gene Mutations in Human Germ Cell Tumors
Tian, Q., Frierson, H. F., Krystal, G. W., & Moskaluk, C. A. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65419-3 · Cited by 408
Marcucci, G., Mrózek, K., Ruppert, A. S., Maharry, K., Kolitz, J. E., Moore, J. O., Mayer, R. J., Pettenati, M. J., Powell, B. L., Edwards, C. G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.15.610 · Cited by 381
Self-citationSchnittger, S., Kohl, T. M., Haferlach, T., Kern, W., Hiddemann, W., Spiekermann, K., & Schoch, C. (2006) · Blood · doi:10.1182/blood-2005-04-1466 · Cited by 380
Cairoli, R. (2006) · Blood · doi:10.1182/blood-2005-09-3640 · Cited by 375
Structure and regulation of Kit protein-tyrosine kinase—The stem cell factor receptor
Roskoski, R. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.150 · Cited by 345
Care, R. S., Valk, P. J. M., Goodeve, A. C., Abu‐Duhier, F. M., Geertsma‐Kleinekoort, W. M. C., Wilson, G. A., Gari, M. A., Peake, I. R., Löwenberg, B., & Reilly, J. T. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04362.x · Cited by 323
KIT Mutations Are Common in Testicular Seminomas
Kemmer, K., Corless, C. L., Fletcher, J. A., McGreevey, L., Haley, A., Griffith, D., Cummings, O. W., Wait, C., Town, A., & Heinrich, M. C. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63120-3 · Cited by 322
Normal and Oncogenic Forms of the Receptor Tyrosine Kinase Kit
Lennartsson, J., Jelacic, T., Linnekin, D., & Shivakrupa, R. (2005) · STEM CELLS · doi:10.1634/stemcells.2004-0117 · Cited by 303
Schoch, C., Kern, W., Schnittger, S., Hiddemann, W., & Haferlach, T. (2004) · Leukemia · doi:10.1038/sj.leu.2403187 · Cited by 284
Wang, Y.-Y., Zhou, G.-B., Yin, T., Chen, B., Shi, J.-Y., Liang, W.-X., Jin, X.-L., You, J.-H., Yang, G., Shen, Z.-X., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408831102 · Cited by 276
c‐kit proto‐oncogene exon 8 in‐frame deletion plus insertion mutations in acute myeloid leukaemia
Gari, M., Goodeve, A., Wilson, G., Winship, P., Langabeer, S., Linch, D., Vandenberghe, E., Peake, I., & Reilly, J. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01449.x · Cited by 262
Gleixner, K. V., Mayerhofer, M., Aichberger, K. J., Derdak, S., Sonneck, K., Böhm, A., Gruze, A., Samorapoompichit, P., Manley, P. W., Fabbro, D., et al. (2006) · Blood · doi:10.1182/blood-2005-07-3022 · Cited by 250
Growney, J. D., Clark, J. J., Adelsperger, J., Stone, R., Fabbro, D., Griffin, J. D., & Gilliland, D. G. (2005) · Blood · doi:10.1182/blood-2004-12-4617 · Cited by 249
Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia
Goemans, B. F., Zwaan, C. M., Miller, M., Zimmermann, M., Harlow, A., Meshinchi, S., Loonen, A. H., Hählen, K., Reinhardt, D., Creutzig, U., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403870 · Cited by 243
Gotlib, J. (2005) · Blood · doi:10.1182/blood-2005-04-1568 · Cited by 243
Core-binding factors in hematopoiesis and immune function
de Bruijn, M. F., & Speck, N. A. (2004) · Oncogene · doi:10.1038/sj.onc.1207763 · Cited by 231
Beghini, A., Ripamonti, C. B., Cairoli, R., et al. (2004) · PubMed · Cited by 161
Blechman, J. M., Lev, S., Barg, J., Eisenstein, M., Vaks, B., Vogel, Z., Givol, D., & Yarden, Y. (1995) · Cell · doi:10.1016/0092-8674(95)90455-7 · Cited by 156
Kolitz, J. E., George, S. L., Dodge, R. K., Hurd, D. D., Powell, B. L., Allen, S. L., Vélez-García, E., Moore, J. O., Shea, T. C., Hoke, E. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.106 · Cited by 150
Self-citationFritsche‐Polanz, R., Jordan, J.-H., Feix, A., Sperr, W. R., Sunder–Plassmann, G., Valent, P., & Födinger, M. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02783.x · Cited by 144
Moore, J. O., George, S. L., Dodge, R. K., Amrein, P. C., Powell, B. L., Kolitz, J. E., Baer, M. R., Davey, F. R., Bloomfield, C. D., Larson, R. A., et al. (2004) · Blood · doi:10.1182/blood-2004-08-2977 · Cited by 138
Self-citationAl‐Ali, H. K., Heinrich, M. C., Lange, T., Krahl, R., Mueller, M., Müller, C., Niederwieser, D. W., Druker, B. J., & Deininger, M. W. (2004) · The Hematology Journal · doi:10.1038/sj.thj.6200319 · Cited by 111
Kohl, T. M., Schnittger, S., Ellwart, J. W., Hiddemann, W., & Spiekermann, K. (2004) · Blood · doi:10.1182/blood-2004-06-2068 · Cited by 97
Nanri, T., Matsuno, N., Kawakita, T., Suzushima, H., Kawano, F., Mitsuya, H., & Asou, N. (2005) · Leukemia · doi:10.1038/sj.leu.2403803 · Cited by 94
Frueh, F. W., & Noyer-Weidner, M. (2003) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2003.068 · Cited by 75
Localization of the human c-kit protooncogene on the q11?q12 region of chromosome 4
d'Auriol, L., Mattéi, M., André, C., & Galibert, F. (1988) · Human Genetics · doi:10.1007/bf00291740 · Cited by 74
Second hit mutations in the RTK/RAS signaling pathway in acute myeloid leukemia with inv(16).
Valk, P. J. M., Bowen, D., Frew, M. E., Goodeve, A. C., Löwenberg, B., & Reilly, J. T. (2004) · PubMed · Cited by 55
Cross, N. C. P., Lin, F., Bungey, J., & Goldman, J. M. (1993) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199309047861 · Cited by 50
Nakai, Y., Nonomura, N., Oka, D., Shiba, M., Arai, Y., Nakayama, M., Inoue, H., Nishimura, K., Aozasa, K., Mizutani, Y., et al. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.042 · Cited by 49
Nanri, T., Matsuno, N., Kawakita, T., Mitsuya, H., & Asou, N. (2005) · Leukemia · doi:10.1038/sj.leu.2403889 · Cited by 27
STI 571 inhibition effect on KITAsn822Lys-mediated signal transduction cascade
Beghini, A., Bellini, M., Magnani, I., Colapietro, P., Cairoli, R., Morra, E., & Larizza, L. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2005.03.007 · Cited by 24
Cited by
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424
Self-citationDöhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Self-citationGrimwade, D., Hills, R. K., Moorman, A. V., Walker, H., Chatters, S., Goldstone, A. H., Wheatley, K., Harrison, C. J., Burnett, A. K., & on behalf of the National Cancer Research Institute Adult Leukaemia Working Group (2010) · Blood · doi:10.1182/blood-2009-11-254441 · Cited by 1,938
‘Acute myeloid leukemia: a comprehensive review and 2016 update’
De Kouchkovsky, I., & Abdul-Hay, M. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.50 · Cited by 1,317
Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update
Pui, C.-H., Carroll, W. L., Meshinchi, S., & Arceci, R. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.7405 · Cited by 842
Metadata
- Authors
- Paschka, P., Marcucci, G., Ruppert, A. S., Mrózek, K., Chen, H., Kittles, R. A., Vukosavljevic, T., Perrotti, D., Vardiman, J. W., Carroll, A. J., Kolitz, J. E., Larson, R. A., & Bloomfield, C. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-08-20
- Volume
- 24
- Issue
- 24
- Pages
- 3904-3911
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2110828128
- Cited by
- 663
- References
- 51
- FWCI
- 18.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.